Acelrx Pharmaceuticals (ACRX) 7.29 $ACRX
AcelRx Pharmaceuticals to Present at BIO CEO & Investor Conference
PR Newswire - Wed Feb 04, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E Morris, Chief Financial Officer, will present a company overview and update at the 17th Annual BIO CEO & Investor Conference. Details of the presentation are as follows:
ACRX: 7.29 (-0.06)
Commit To Purchase AcelRx Pharmaceuticals At $5, Earn 17.1% Annualized Using Options
StockOptionsChannel.com - Mon Jan 26, 10:40AM CST
Investors considering a purchase of AcelRx Pharmaceuticals Inc shares, but tentative about paying the going market price of $6.73/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
ACRX: 7.29 (-0.06)
Will the Second Time be a Charm for Biotech AcelRx After Their FDA Rejection?
at The Street - Thu Jan 15, 8:59AM CST
AcelRx Pharmaceuticals was hit with an FDA rejection and is due to resubmit their drug this quarter; should investors stay away or is there an opportunity to be had?
ACRX: 7.29 (-0.06)
AcelRx (ACRX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 5:46AM CST
AcelRx (ACRX) Shares March Higher, Can It Continue?
ACRX: 7.29 (-0.06)
5 Stocks Under $10 Setting Up to Trade Higher: Callon Petroleum and More
at The Street - Fri Jan 09, 9:32AM CST
These setups often produce monster moves higher in very short time frames.
ACRX: 7.29 (-0.06), NOG: 8.76 (+0.38), CPE: 7.37 (+0.27), PHMD: 1.68 (+0.04), NKA: 1.68 (+0.13)
Minerva Neurosciences (NERV) in Focus: Stock Jumps 8.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 8:21AM CST
Minerva Neurosciences, Inc. (NERV) was a big mover last session, as the company saw its shares rise over 8% on the day.
ACRX: 7.29 (-0.06), NERV: 4.68 (+0.09)
Cempra (CEMP) in Focus: Stock Rises 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:44AM CST
Cempra, Inc. (CEMP) was a big mover last session, as the company saw its shares gain over 7%
ACRX: 7.29 (-0.06), CEMP: 27.68 (+1.25)
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
BAM: 54.40 (+0.93), AGN: 229.49 (+1.87), ACRX: 7.29 (-0.06), COLB: 27.85 (+0.22), CALD: 14.95 (+0.03)
A Little Impatience And A Lot Of Skepticism Provides An Excellent Risk-Reward In AcelRx Pharmaceuticals
Buddy Lyons - at Seeking Alpha - Thu Jan 01, 5:00AM CST
ACRX: 7.29 (-0.06)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
BIRT: 6.60 (+0.01), ACRX: 7.29 (-0.06), AWR: 39.04 (-0.23), ABBV: 58.05 (+1.00), ALGT: 178.42 (-4.07)
AcelRx Pharmaceuticals (ACRX) Downgraded From Hold to Sell
at The Street - Tue Dec 30, 9:00AM CST
AcelRx Pharmaceuticals (ACRX) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D.
ACRX: 7.29 (-0.06)
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
BIRT: 6.60 (+0.01), ACRX: 7.29 (-0.06), AWR: 39.04 (-0.23), ACPW: 1.86 (unch), ADUS: 21.57 (+0.18)
Xencor, Inc. (XNCR) in Focus: Stock Soars 29.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 8:21AM CST
Xencor, Inc. (XNCR) was a big mover last session, as the company saw its shares rise by nearly 30% on the day.
ACRX: 7.29 (-0.06), XNCR: 15.47 (-0.22)
Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 14.92 (+0.93), ACRX: 7.29 (-0.06), EGLT: 10.60 (+0.58), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14)
Weakness Seen in Infinity Pharmaceuticals (INFI): Stock Falls 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:30AM CST
Shares of Infinity Pharmaceuticals (INFI) fell over 12% on the day. This reverses the most recent downtrend for INFI, as the stock is up nearly 15% since Nov 19. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
ACRX: 7.29 (-0.06), LCI: 57.78 (-0.91), INFI: 15.13 (+0.55), IG: 10.57 (-0.12)
La Jolla Pharmaceutical (LJPC) Jumps: Stock Gains 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:11AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
ACRX: 7.29 (-0.06), LCI: 57.78 (-0.91), LJPC: 18.79 (unch), IG: 10.57 (-0.12)
Sedation - Pipeline Review, H1 2014
M2 - Thu Dec 11, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/fxkbln/sedation) has announced the addition of the "Sedation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Sedation - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AstraZeneca - AcelRx Pharmaceuticals - Paion - Maruishi Pharmaceutical - NanoMedex Pharmaceuticals - Advicenne Pharma For more information visit http://www.researchandmarkets.com/research/fxkbln/sedation
ACRX: 7.29 (-0.06)
Why AcelRx Pharmaceuticals (ACRX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 7:31AM CST
AcelRx Pharmaceuticals could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
ACRX: 7.29 (-0.06)
AcelRx Pharmaceuticals to Present at BIO CEO & Investor Conference
PR Newswire - Wed Feb 04, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E Morris, Chief Financial Officer, will present a company overview and update at the 17th Annual BIO CEO & Investor Conference. Details of the presentation are as follows:
ACRX: 7.29 (-0.06)
Commit To Purchase AcelRx Pharmaceuticals At $5, Earn 17.1% Annualized Using Options
StockOptionsChannel.com - Mon Jan 26, 10:40AM CST
Investors considering a purchase of AcelRx Pharmaceuticals Inc shares, but tentative about paying the going market price of $6.73/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
ACRX: 7.29 (-0.06)
Will the Second Time be a Charm for Biotech AcelRx After Their FDA Rejection?
at The Street - Thu Jan 15, 8:59AM CST
AcelRx Pharmaceuticals was hit with an FDA rejection and is due to resubmit their drug this quarter; should investors stay away or is there an opportunity to be had?
ACRX: 7.29 (-0.06)
AcelRx (ACRX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 5:46AM CST
AcelRx (ACRX) Shares March Higher, Can It Continue?
ACRX: 7.29 (-0.06)
5 Stocks Under $10 Setting Up to Trade Higher: Callon Petroleum and More
at The Street - Fri Jan 09, 9:32AM CST
These setups often produce monster moves higher in very short time frames.
ACRX: 7.29 (-0.06), NOG: 8.76 (+0.38), CPE: 7.37 (+0.27), PHMD: 1.68 (+0.04), NKA: 1.68 (+0.13)
Minerva Neurosciences (NERV) in Focus: Stock Jumps 8.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 8:21AM CST
Minerva Neurosciences, Inc. (NERV) was a big mover last session, as the company saw its shares rise over 8% on the day.
ACRX: 7.29 (-0.06), NERV: 4.68 (+0.09)
Cempra (CEMP) in Focus: Stock Rises 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:44AM CST
Cempra, Inc. (CEMP) was a big mover last session, as the company saw its shares gain over 7%
ACRX: 7.29 (-0.06), CEMP: 27.68 (+1.25)
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
BAM: 54.40 (+0.93), AGN: 229.49 (+1.87), ACRX: 7.29 (-0.06), COLB: 27.85 (+0.22), CALD: 14.95 (+0.03)
A Little Impatience And A Lot Of Skepticism Provides An Excellent Risk-Reward In AcelRx Pharmaceuticals
Buddy Lyons - at Seeking Alpha - Thu Jan 01, 5:00AM CST
ACRX: 7.29 (-0.06)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
BIRT: 6.60 (+0.01), ACRX: 7.29 (-0.06), AWR: 39.04 (-0.23), ABBV: 58.05 (+1.00), ALGT: 178.42 (-4.07)
AcelRx Pharmaceuticals (ACRX) Downgraded From Hold to Sell
at The Street - Tue Dec 30, 9:00AM CST
AcelRx Pharmaceuticals (ACRX) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D.
ACRX: 7.29 (-0.06)
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
BIRT: 6.60 (+0.01), ACRX: 7.29 (-0.06), AWR: 39.04 (-0.23), ACPW: 1.86 (unch), ADUS: 21.57 (+0.18)
Xencor, Inc. (XNCR) in Focus: Stock Soars 29.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 8:21AM CST
Xencor, Inc. (XNCR) was a big mover last session, as the company saw its shares rise by nearly 30% on the day.
ACRX: 7.29 (-0.06), XNCR: 15.47 (-0.22)
Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 14.92 (+0.93), ACRX: 7.29 (-0.06), EGLT: 10.60 (+0.58), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14)
Weakness Seen in Infinity Pharmaceuticals (INFI): Stock Falls 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:30AM CST
Shares of Infinity Pharmaceuticals (INFI) fell over 12% on the day. This reverses the most recent downtrend for INFI, as the stock is up nearly 15% since Nov 19. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
ACRX: 7.29 (-0.06), LCI: 57.78 (-0.91), INFI: 15.13 (+0.55), IG: 10.57 (-0.12)
La Jolla Pharmaceutical (LJPC) Jumps: Stock Gains 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:11AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
ACRX: 7.29 (-0.06), LCI: 57.78 (-0.91), LJPC: 18.79 (unch), IG: 10.57 (-0.12)
Sedation - Pipeline Review, H1 2014
M2 - Thu Dec 11, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/fxkbln/sedation) has announced the addition of the "Sedation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Sedation - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AstraZeneca - AcelRx Pharmaceuticals - Paion - Maruishi Pharmaceutical - NanoMedex Pharmaceuticals - Advicenne Pharma For more information visit http://www.researchandmarkets.com/research/fxkbln/sedation
ACRX: 7.29 (-0.06)
Why AcelRx Pharmaceuticals (ACRX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 7:31AM CST
AcelRx Pharmaceuticals could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
ACRX: 7.29 (-0.06)
